FDA
-
-
-
-
-
-
-
Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
Magenta Therapeutics (MGTA) Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
-
-
-
-
-
-
-
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
Magenta Therapeutics (MGTA) receives clinical hold letter from FDA related to IND to initiate Phase 1/2 clinical trial of MGTA-117 in patients with AML and MDS
-
-
-
-
-
-
-
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights
-
-
-
-
-
-
-
Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Pre-Open Stock Movers 04/30: (PI) (GTHX) (WAGE) Higher; (CGNX) (TREX) (GOOGL) Lower (more...)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

